Inflammation Gastrointestinal TractNCT07591961
Identifying the Microbial Metabolome: The Missing Link Between Diet and Human Health
A study testing Food in people with Inflammation Gastrointestinal Tract, run by University of Aberdeen.
Trial summary
There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation Gastrointestinal Tract
- What is being tested?
- Food
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- No sites listed yet
- Study dates
- 23 May 2016to 4 Sep 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy male or females
- aged between 18 and 55 years
- able to give informed consent.
Who cannot join
- are taking any medicines prescribed by their GP
- are taking drugs to lower high cholesterol levels or high blood pressure
- regularly take analgesics, antipyretic or anti-inflammatories
- regularly take nutritional supplements
- have taken antibiotics in the last three months
- have given a large blood donation in last three months
About this study
Official title: Identifying Microbial Metabolites and the Bacteria Responsible for Their Formation
There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. We will also identify which bacteria are responsible for these changes. The foods we will look at are those suggested by the American Institute of Cancer Research to help prevent cancer; leafy green vegetables (cabbage, spinach), soft fruits (strawberry) cereal (oats) and plant-based protein (soya and pea). We will feed a diet rich in these foods to volunteers, monitoring the changes to the bacteria in our gut and the products produced. We will identify which products have potential to prevent cancer and also to work out how they are being produced. This work will provide new and important information that will allow us to understand more about the link between diet and health.
Read the detailed description
An accumulation of evidence indicates that the gut microbiota plays a vital role in inflammation and in the development of many diseases including diabetes, cardiovascular disease and cancer (Vijay-Kumar et al; 2010, Masklowski et al; 2009, Clarke et al 2010). Despite tremendous advances in the molecular approaches describing the composition of the human gut microbiota (Qin et al; 2012), to date relatively little is known about the functionality and role of even the most dominant commensal organisms within the human host. It is widely accepted that the products of microbial metabolism influence human health and disease, particularly regarding inflammation and immune responses. Despite this, many of the products of microbial metabolism of dietary compounds remain uncharacterised and consequently, their mechanisms of action unknown. As an enormous investment is being made to continue to characterise the microbiome and its interaction with the human immune system, there is now a critical requirement that the functional role of the microbiota is established. It is important that in addition to describing the microbial populations, the species are also defined by their function and metabolic outputs. This topic is exceptionally timely as there is increasing pressure to provide healthy food to a growing and increasingly unhealthy and aging population. Elucidating the products of microbial metabolism provides an essential and missing link between well-defined dietary intakes and the physiological effect of dietary constituents. Without this information, the nutritional value of food cannot be fully established, food claims effectively evaluated, nor the contribution of the gut microbiota to an overall aim of developing sustainable agricultural products beneficial for human health ascertained.
Diet, is a major factor shaping the composition of the colonic microbial community as well as a principal determinant of the gut metabolome. This is likely to explain why it is also a contributing factor in disease development and progression. Two related dietary factors appear to play a significant role in maintaining the equilibrium between health and disease. Firstly, the balance between different types of carbohydrate and protein is fundamental. Dietary fibre intake is strongly correlated with prevention of carcinogenesis and evidence that high protein-low carbohydrate diets are detrimental to health is increasing. Secondly, there is a large amount of literature suggesting that plant secondary metabolites have anti-cancer properties. In particular, almost all plant foods considered to have cancer-preventative properties are rich in non-nutrient compounds derived from the phenylpropanoid pathway. Much of the evidence for this however is obtained from in vitro data and there is very little evidence from both pre-clinical and human interventions to support their bioavailability and role in carcinogenesis. Data regarding the metabolism and bioavailability of phytochemicals is lacking, particularly with reference to transformation by the gut microbiota and absorption from the colon via the hepatic circulation. Additionally, the relationship between the main macronutrients (carbohydrate and protein) and non-nutrient phytochemicals is poorly understood. It is likely that it is a combination of these dietary factors that modulates both the gut bacteria and the overall metabolite profile, both in the gut and in the systemic circulation. This unique proposal will address the combined effects of the macro- and non-nutrient components of the diet, along with the gut microbial composition on the production of microbial metabolites.
Study Objectives
Specific objectives of the project are to:
- Fully characterise dietary substrates in terms of their macro-, micro- and non-nutrient phytochemicals, providing the basis for detailed in vitro work and rigorous human intervention studies.
- Identify the microbial metabolites which exhibit inflammatory activity at relevant in vivo concentrations. This will provide essential information, not currently available and will inform wider studies looking at the action of microbial metabolites on particular receptors and biomarkers of health.
- Determine the functionality of the bacterial species responsible in terms of metabolite production. In this context, this will also identify the extent of redundancy of certain species.
- Establish the role of major macronutrients in driving microbial metabolism, both in the production of phytochemical metabolites and the provision of carbohydrate and protein by-products.
Hypothesis Phytochemicals bound to plant polymers reach the colon largely intact and are metabolised and released by the gut microbiota where they can exert a direct anti-inflammatory action on the gut mucosa. Additionally mucosal uptake of these metabolites will suppress low-level chronic systemic inflammation. Furthermore, the source and type of polymer may improve or exacerbate the effect.
- Conditions
- Inflammation Gastrointestinal Tract
- Being tested
- Food
- Keywords
- Microbiome, Metabolome, Dietary Metabolites, Macronutrient Balance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FoodDietary supplement
The intervention products will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period, in addition to the prescribed low-phytochemical diet.
| Study group | Role | What they receive |
|---|---|---|
| oat | Active comparator | The intervention products will be commercially available oat provided as freeze dried powders baked into a bun. Receives: Dietary Supplement: Food |
| pea | Active comparator | The intervention products will be commercially available pea provided as freeze dried powders baked into a bun. Receives: Dietary Supplement: Food |
| soya | Active comparator | The intervention products will be commercially available soya provided as freeze dried powders baked into a bun. Receives: Dietary Supplement: Food |
| strawberry | Active comparator | The intervention products will be commercially available strawberry provided as freeze dried powders. The product will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period Receives: Dietary Supplement: Food |
| spinach | Active comparator | The intervention products will be commercially available spinach provided as freeze dried powders baked into a bun. Receives: Dietary Supplement: Food |
| kale | Active comparator | The intervention products will be commercially available kale provided as freeze dried powders baked into a bun. Receives: Dietary Supplement: Food |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut Microbial Metabolites
Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine
Measured: At Day 3
Gut Microbial Metabolites
Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine
Measured: At Day 5
Secondary outcomes (2)
Gut Microbial Species
Bacteria
Wide range of gut bacteria present in faecal samples
Measured: At Day 3
Gut Microbial Species
Bacteria
Measured: At Day 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2026
- Study start23 May 2016
- Primary completion30 Aug 2019
- Study completion4 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Inflammation Gastrointestinal TractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- Participants receive five alternative interventions during the period of the study
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aberdeen
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Wendy R Russell, PhD, Principal investigator, University of Aberdeen Rowett Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07591961
- Sponsor's protocol ID
- 15/HSMC/005
- Other IDs
- U01CA179531
- Status last verified
- Feb 2020
- First submitted
- 12 Feb 2020
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying Microbial Metabolites and the Bacteria Responsible for Their Formation
- ClinicalTrials.gov ID
- NCT07591961
- Acronym / sponsor ID
- 15/HSMC/005
- Conditions
- Inflammation Gastrointestinal Tract
- Keywords
- Microbiome, Metabolome, Dietary Metabolites, Macronutrient Balance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- University of AberdeenUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 23 May 2016 (actual)
- Primary completion
- 30 Aug 2019 (actual)
- Study completion
- 4 Sep 2019 (actual)
- First posted
- 18 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. We will also identify which bacteria are responsible for these changes. The foods we will look at are those suggested by the American Institute of Cancer Research to help prevent cancer; leafy green vegetables (cabbage, spinach), soft fruits (strawberry) cereal (oats) and plant-based protein (soya and pea). We will feed a diet rich in these foods to volunteers, monitoring the changes to the bacteria in our gut and the products produced. We will identify which products have potential to prevent cancer and also to work out how they are being produced. This work will provide new and important information that will allow us to understand more about the link between diet and health.
Detailed description
An accumulation of evidence indicates that the gut microbiota plays a vital role in inflammation and in the development of many diseases including diabetes, cardiovascular disease and cancer (Vijay-Kumar et al; 2010, Masklowski et al; 2009, Clarke et al 2010). Despite tremendous advances in the molecular approaches describing the composition of the human gut microbiota (Qin et al; 2012), to date relatively little is known about the functionality and role of even the most dominant commensal organisms within the human host. It is widely accepted that the products of microbial metabolism influence human health and disease, particularly regarding inflammation and immune responses. Despite this, many of the products of microbial metabolism of dietary compounds remain uncharacterised and consequently, their mechanisms of action unknown. As an enormous investment is being made to continue to characterise the microbiome and its interaction with the human immune system, there is now a critical requirement that the functional role of the microbiota is established. It is important that in addition to describing the microbial populations, the species are also defined by their function and metabolic outputs. This topic is exceptionally timely as there is increasing pressure to provide healthy food to a growing and increasingly unhealthy and aging population. Elucidating the products of microbial metabolism provides an essential and missing link between well-defined dietary intakes and the physiological effect of dietary constituents. Without this information, the nutritional value of food cannot be fully established, food claims effectively evaluated, nor the contribution of the gut microbiota to an overall aim of developing sustainable agricultural products beneficial for human health ascertained.
Diet, is a major factor shaping the composition of the colonic microbial community as well as a principal determinant of the gut metabolome. This is likely to explain why it is also a contributing factor in disease development and progression. Two related dietary factors appear to play a significant role in maintaining the equilibrium between health and disease. Firstly, the balance between different types of carbohydrate and protein is fundamental. Dietary fibre intake is strongly correlated with prevention of carcinogenesis and evidence that high protein-low carbohydrate diets are detrimental to health is increasing. Secondly, there is a large amount of literature suggesting that plant secondary metabolites have anti-cancer properties. In particular, almost all plant foods considered to have cancer-preventative properties are rich in non-nutrient compounds derived from the phenylpropanoid pathway. Much of the evidence for this however is obtained from in vitro data and there is very little evidence from both pre-clinical and human interventions to support their bioavailability and role in carcinogenesis. Data regarding the metabolism and bioavailability of phytochemicals is lacking, particularly with reference to transformation by the gut microbiota and absorption from the colon via the hepatic circulation. Additionally, the relationship between the main macronutrients (carbohydrate and protein) and non-nutrient phytochemicals is poorly understood. It is likely that it is a combination of these dietary factors that modulates both the gut bacteria and the overall metabolite profile, both in the gut and in the systemic circulation. This unique proposal will address the combined effects of the macro- and non-nutrient components of the diet, along with the gut microbial composition on the production of microbial metabolites.
Study Objectives
Specific objectives of the project are to:
- Fully characterise dietary substrates in terms of their macro-, micro- and non-nutrient phytochemicals, providing the basis for detailed in vitro work and rigorous human intervention studies.
- Identify the microbial metabolites which exhibit inflammatory activity at relevant in vivo concentrations. This will provide essential information, not currently available and will inform wider studies looking at the action of microbial metabolites on particular receptors and biomarkers of health.
- Determine the functionality of the bacterial species responsible in terms of metabolite production. In this context, this will also identify the extent of redundancy of certain species.
- Establish the role of major macronutrients in driving microbial metabolism, both in the production of phytochemical metabolites and the provision of carbohydrate and protein by-products.
Hypothesis Phytochemicals bound to plant polymers reach the colon largely intact and are metabolised and released by the gut microbiota where they can exert a direct anti-inflammatory action on the gut mucosa. Additionally mucosal uptake of these metabolites will suppress low-level chronic systemic inflammation. Furthermore, the source and type of polymer may improve or exacerbate the effect.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- Participants receive five alternative interventions during the period of the study
| Arm | Type | Receives |
|---|---|---|
| oat | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available oat provided as freeze dried powders baked into a bun. |
| pea | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available pea provided as freeze dried powders baked into a bun. |
| soya | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available soya provided as freeze dried powders baked into a bun. |
| strawberry | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available strawberry provided as freeze dried powders. The product will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period |
| spinach | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available spinach provided as freeze dried powders baked into a bun. |
| kale | Active comparator | Dietary Supplement: FoodThe intervention products will be commercially available kale provided as freeze dried powders baked into a bun. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- healthy male or females
- aged between 18 and 55 years
- able to give informed consent.
Key exclusion criteria (6 listed)
- are taking any medicines prescribed by their GP
- are taking drugs to lower high cholesterol levels or high blood pressure
- regularly take analgesics, antipyretic or anti-inflammatories
- regularly take nutritional supplements
- have taken antibiotics in the last three months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FoodThe intervention products will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period, in addition to the prescribed low-phytochemical diet. | Dietary supplement | kale, oat, pea, soya, spinach, strawberry |
Primary outcome
Gut Microbial Metabolites
Time frame: At Day 3
Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine
Gut Microbial Metabolites
Time frame: At Day 5
Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine
2 secondary outcomes
Gut Microbial Species
Time frame: At Day 3
Gut Microbial Species
Time frame: At Day 5
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Inflammation Gastrointestinal Tract
Active, not recruitingObservational study
Early Predictors of Necrotizing Enterocolitis in Neonates
Necrotizing Enterocolitis
Not yet recruiting
Study on the Mechanism of Central Obesity Induced by Sleep Restriction and the Therapeutic Effect of n-3 Polyunsaturated Fatty Acid: a Randomized, Double-blind, Placebo-controlled Trial (COSPA Study)
Sleep Deprivation
Recruiting
The Impact of Overnight Active Temperature Regulation on the Gut Microbiome, Inflammation, and Circadian Rhythm.
Poor Sleep Quality, Gut Microbiome
Recruiting
Changes in Intestinal Permeability and Systemic Inflammation Following Fast Food Overfeeding.
Obesity & Overweight
Not yet recruitingObservational study
Type 2 Inflammation in Adults With Cystic Fibrosis
Cystic Fibrosis (CF), Type 2 Inflammatory Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wendy R Russell, PhD principal investigator
University of Aberdeen Rowett Institute
Questions about this trial
What is this clinical trial studying?
A study testing Food in people with Inflammation Gastrointestinal Tract, run by University of Aberdeen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut Microbial Metabolites (time frame: At Day 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.